Pharmocann Global Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Pharmocann Global has been growing earnings at an average annual rate of 15.6%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 9.1% per year.
Belangrijke informatie
15.6%
Groei van de winst
40.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 35.1% |
| Inkomstengroei | -9.1% |
| Rendement op eigen vermogen | -4,587.4% |
| Nettomarge | -76.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence
Mar 30
Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?
Feb 04Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Dec 31
The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come
Nov 26Opbrengsten en kosten
Hoe Pharmocann Global geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 13 | -10 | 8 | 0 |
| 31 Mar 24 | 14 | -10 | 8 | 0 |
| 31 Dec 23 | 14 | -10 | 8 | 0 |
| 30 Sep 23 | 11 | -12 | 6 | 0 |
| 30 Jun 23 | 12 | -18 | 7 | 1 |
| 31 Mar 23 | 17 | -24 | 10 | 1 |
| 31 Dec 22 | 23 | -25 | 13 | 1 |
| 30 Sep 22 | 24 | -23 | 12 | 1 |
| 30 Jun 22 | 25 | -20 | 13 | 1 |
| 31 Mar 22 | 28 | -16 | 15 | 1 |
| 31 Dec 21 | 29 | -19 | 15 | 1 |
| 30 Sep 21 | 31 | -14 | 15 | 1 |
| 30 Jun 21 | 32 | -7 | 15 | 1 |
| 31 Mar 21 | 31 | 2 | 13 | 1 |
| 31 Dec 20 | 28 | 4 | 13 | 1 |
| 30 Sep 20 | 26 | 6 | 11 | 1 |
| 30 Jun 20 | 26 | 5 | 10 | 1 |
| 31 Mar 20 | 21 | -25 | 9 | 1 |
| 31 Dec 19 | 21 | -46 | 6 | 1 |
| 30 Sep 19 | 18 | -46 | 6 | 0 |
| 30 Jun 19 | 17 | -46 | 4 | 0 |
| 31 Mar 19 | 16 | -20 | 4 | 0 |
| 31 Dec 18 | 15 | 6 | 3 | 0 |
| 31 Dec 17 | 12 | 2 | 3 | 0 |
| 31 Dec 16 | 9 | 1 | 2 | 0 |
Kwaliteitswinsten: PMCN-M is currently unprofitable.
Groeiende winstmarge: PMCN-M is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PMCN-M is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.
Versnelling van de groei: Unable to compare PMCN-M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: PMCN-M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).
Rendement op eigen vermogen
Hoge ROE: PMCN-M has a negative Return on Equity (-4587.44%), as it is currently unprofitable.